SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Themis Medicare rises on getting DCGI’s nod to import, market Remifentanil 1mg/2mg Powder for Injection

Themis Medicare Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 530199 | NSE: THEMISMED

17 Feb 2023 Evaluate

Themis Medicare is currently trading at Rs. 1354.00, up by 10.40 points or 0.77% from its previous closing of Rs. 1343.60 on the BSE.

The scrip opened at Rs. 1359.90 and has touched a high and low of Rs. 1372.75 and Rs. 1337.70 respectively. So far 710 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1434.25 on 16-Dec-2022 and a 52 week low of Rs. 692.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 1372.75 and Rs. 1296.80 respectively. The current market cap of the company is Rs. 1246.06 crore.

The promoters holding in the company stood at 67.18%, while Institutions and Non-Institutions held 0.03% and 32.79% respectively.

Themis Medicare has received approval from Drug Controller General of India (DCGI) for import & marketing of Remifentanil 1mg/2mg Powder for Concentrate for Solution for Injection. The drug been approved for use as an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures, for continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting, and as an analgesic component of monitored anesthesia care in adult patients. Themis will market this drug with the brand name Remithem.

Remifentanil is short-acting narcotic analgesic with a rapid onset & rapid offset of action that offers easy dose titration, predictable and precise intraoperative control, and reduced or rapidly reversed side effects. Due to its distinct pharmacokinetic and pharmacodynamic properties and rapid extra-hepatic clearance, Remifentanil has several applications in general anesthesia and in intensive care where rapid clearance of drug is beneficial.

Remifentanil was first approved by USFDA in 1996. With the current approval in India, the long wait for the rapid acting narcotic analgesic is over. Remithem will be imported by Themis and marketed in India soon by its well-trained sales team which is currently marketing a range of anesthesia and critical care products to hospitals across the country.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.

Themis Medicare Share Price

90.25 4.97 (5.83%)

17-Apr-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1675.20
Dr. Reddys Lab	1235.40
Cipla	1238.30
Zydus Lifesciences	942.55
Lupin	2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Themis Medicare rises on getting DCGI’s nod to import, market Remifentanil 1mg/2mg Powder for Injection

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.